GSK (NYSE:GSK) Stock Unloaded Rep. Lisa C. McClain

25 Nov 2025, 17:18 by Doug Wharley · The Cerbat Gem

Representative Lisa C. McClain (R-Michigan) recently sold shares of GSK PLC Sponsored ADR (NYSE:GSK). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in GSK stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

GSK Trading Up 1.3%

Shares of NYSE GSK traded up $0.60 during midday trading on Tuesday, hitting $47.59. 6,602,140 shares of the company traded hands, compared to its average volume of 5,173,291. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $48.69. The firm has a market cap of $96.62 billion, a P/E ratio of 13.44, a P/E/G ratio of 1.90 and a beta of 0.50. The stock has a 50-day moving average price of $44.37 and a 200 day moving average price of $40.85. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87.

GSK (NYSE:GSK – Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.22. GSK had a return on equity of 51.07% and a net margin of 17.16%.The business had revenue of $11.35 billion for the quarter, compared to analysts’ expectations of $8.21 billion. During the same period in the previous year, the firm posted $0.50 EPS. The business’s revenue was up 6.7% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. As a group, analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 8th. Investors of record on Friday, November 14th will be given a dividend of $0.4171 per share. The ex-dividend date is Friday, November 14th. This represents a $1.67 annualized dividend and a dividend yield of 3.5%. GSK’s payout ratio is currently 46.05%.

Institutional Investors Weigh In On GSK

Institutional investors and hedge funds have recently made changes to their positions in the company. Dodge & Cox lifted its position in GSK by 14.9% in the 1st quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock valued at $3,046,972,000 after acquiring an additional 10,210,921 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of GSK by 2.8% in the third quarter. Fisher Asset Management LLC now owns 32,227,615 shares of the pharmaceutical company’s stock worth $1,390,944,000 after purchasing an additional 889,210 shares during the last quarter. Primecap Management Co. CA lifted its holdings in shares of GSK by 1.8% during the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company’s stock valued at $995,929,000 after purchasing an additional 446,360 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of GSK by 2.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company’s stock valued at $299,163,000 after buying an additional 155,392 shares during the last quarter. Finally, Royal Bank of Canada boosted its position in shares of GSK by 5.7% during the first quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company’s stock valued at $293,692,000 after buying an additional 411,869 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GSK. Bank of America upgraded GSK from an “underperform” rating to a “neutral” rating in a research report on Tuesday. Weiss Ratings reissued a “buy (b)” rating on shares of GSK in a research report on Thursday. Cfra set a $53.00 price objective on shares of GSK in a report on Thursday, October 30th. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of GSK in a report on Monday, October 27th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, GSK currently has an average rating of “Hold” and an average target price of $44.13.

View Our Latest Report on GSK

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

GSK Company Profile

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.